Cholelithiasis associated with medroxyprogesterone acetate therapy in men

Walter Meyer, I. Wiener, L. E. Emory, C. M. Cole, N. Isenberg, C. J. Fagan, J. C. Thompson

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Five out of forty-five adult men, 50 years of age or less, who had received, for at least six months, medroxyprogesterone acetate (MPA, Depo Provera(R)) IM, 200-400 mg/week, for prevention of sex-offending or genital- mutilating behavior developed symptomatic cholelithiasis. Thirty of these men were studied with gallbladder ultrasound prospectively off MPA and at six- month intervals while taking the medication and then six months off MPA. Gallstones recovered from two patients were found to have very high cholesterol content, suggesting they were formed in cholesterol supersaturated bile. These findings are consistent with the increased incidence of gallbladder disease related to high-progesterone states and suggest that MPA may be a causative agent in cholelithiasis. The physiologic studies on gallbladder contraction and cholecystokinin release in a subset of the patients failed to provide information on a mechanism for the possible increased incidence of gallbladder disease.

Original languageEnglish
Pages (from-to)69-84
Number of pages16
JournalResearch Communications in Chemical Pathology and Pharmacology
Volume75
Issue number1
StatePublished - 1992

Fingerprint

Gallbladder Diseases
Medroxyprogesterone Acetate
Cholelithiasis
Gallbladder
Cholesterol
Cholecystokinin
Incidence
Gallstones
Bile
Progesterone
Ultrasonics
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Meyer, W., Wiener, I., Emory, L. E., Cole, C. M., Isenberg, N., Fagan, C. J., & Thompson, J. C. (1992). Cholelithiasis associated with medroxyprogesterone acetate therapy in men. Research Communications in Chemical Pathology and Pharmacology, 75(1), 69-84.

Cholelithiasis associated with medroxyprogesterone acetate therapy in men. / Meyer, Walter; Wiener, I.; Emory, L. E.; Cole, C. M.; Isenberg, N.; Fagan, C. J.; Thompson, J. C.

In: Research Communications in Chemical Pathology and Pharmacology, Vol. 75, No. 1, 1992, p. 69-84.

Research output: Contribution to journalArticle

Meyer, W, Wiener, I, Emory, LE, Cole, CM, Isenberg, N, Fagan, CJ & Thompson, JC 1992, 'Cholelithiasis associated with medroxyprogesterone acetate therapy in men', Research Communications in Chemical Pathology and Pharmacology, vol. 75, no. 1, pp. 69-84.
Meyer, Walter ; Wiener, I. ; Emory, L. E. ; Cole, C. M. ; Isenberg, N. ; Fagan, C. J. ; Thompson, J. C. / Cholelithiasis associated with medroxyprogesterone acetate therapy in men. In: Research Communications in Chemical Pathology and Pharmacology. 1992 ; Vol. 75, No. 1. pp. 69-84.
@article{5fb32b3d43ff475fa5697fccd9aac985,
title = "Cholelithiasis associated with medroxyprogesterone acetate therapy in men",
abstract = "Five out of forty-five adult men, 50 years of age or less, who had received, for at least six months, medroxyprogesterone acetate (MPA, Depo Provera(R)) IM, 200-400 mg/week, for prevention of sex-offending or genital- mutilating behavior developed symptomatic cholelithiasis. Thirty of these men were studied with gallbladder ultrasound prospectively off MPA and at six- month intervals while taking the medication and then six months off MPA. Gallstones recovered from two patients were found to have very high cholesterol content, suggesting they were formed in cholesterol supersaturated bile. These findings are consistent with the increased incidence of gallbladder disease related to high-progesterone states and suggest that MPA may be a causative agent in cholelithiasis. The physiologic studies on gallbladder contraction and cholecystokinin release in a subset of the patients failed to provide information on a mechanism for the possible increased incidence of gallbladder disease.",
author = "Walter Meyer and I. Wiener and Emory, {L. E.} and Cole, {C. M.} and N. Isenberg and Fagan, {C. J.} and Thompson, {J. C.}",
year = "1992",
language = "English",
volume = "75",
pages = "69--84",
journal = "Research Communications in Chemical Pathology and Pharmacology",
issn = "0034-5164",
publisher = "PJD Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Cholelithiasis associated with medroxyprogesterone acetate therapy in men

AU - Meyer, Walter

AU - Wiener, I.

AU - Emory, L. E.

AU - Cole, C. M.

AU - Isenberg, N.

AU - Fagan, C. J.

AU - Thompson, J. C.

PY - 1992

Y1 - 1992

N2 - Five out of forty-five adult men, 50 years of age or less, who had received, for at least six months, medroxyprogesterone acetate (MPA, Depo Provera(R)) IM, 200-400 mg/week, for prevention of sex-offending or genital- mutilating behavior developed symptomatic cholelithiasis. Thirty of these men were studied with gallbladder ultrasound prospectively off MPA and at six- month intervals while taking the medication and then six months off MPA. Gallstones recovered from two patients were found to have very high cholesterol content, suggesting they were formed in cholesterol supersaturated bile. These findings are consistent with the increased incidence of gallbladder disease related to high-progesterone states and suggest that MPA may be a causative agent in cholelithiasis. The physiologic studies on gallbladder contraction and cholecystokinin release in a subset of the patients failed to provide information on a mechanism for the possible increased incidence of gallbladder disease.

AB - Five out of forty-five adult men, 50 years of age or less, who had received, for at least six months, medroxyprogesterone acetate (MPA, Depo Provera(R)) IM, 200-400 mg/week, for prevention of sex-offending or genital- mutilating behavior developed symptomatic cholelithiasis. Thirty of these men were studied with gallbladder ultrasound prospectively off MPA and at six- month intervals while taking the medication and then six months off MPA. Gallstones recovered from two patients were found to have very high cholesterol content, suggesting they were formed in cholesterol supersaturated bile. These findings are consistent with the increased incidence of gallbladder disease related to high-progesterone states and suggest that MPA may be a causative agent in cholelithiasis. The physiologic studies on gallbladder contraction and cholecystokinin release in a subset of the patients failed to provide information on a mechanism for the possible increased incidence of gallbladder disease.

UR - http://www.scopus.com/inward/record.url?scp=0026566372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026566372&partnerID=8YFLogxK

M3 - Article

C2 - 1385654

AN - SCOPUS:0026566372

VL - 75

SP - 69

EP - 84

JO - Research Communications in Chemical Pathology and Pharmacology

JF - Research Communications in Chemical Pathology and Pharmacology

SN - 0034-5164

IS - 1

ER -